Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D9DS8O
|
|||
Drug Name |
NDV-3A
|
|||
Drug Type |
Vaccine
|
|||
Indication | Staphylococcus infection [ICD-11: 1B5Y; ICD-10: A49.0; ICD-9: 001-139] | Phase 2 | [1] | |
Vulvovaginal Candidiasis [ICD-11: 1F23.10] | Phase 2 | [2] | ||
Candidiasis [ICD-11: 1F23] | Phase 1/2 | [3] | ||
Company |
NovaDigm Therapeutics
|
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT03455309) Evaluation of NDV-3A Vaccine in Preventing S. Aureus Colonization. U.S. National Institutes of Health. | |||
REF 2 | ClinicalTrials.gov (NCT01926028) Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis. U.S. National Institutes of Health. | |||
REF 3 | ClinicalTrials.gov (NCT01926028) Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis. U.S. National Institutes of Health. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.